Handelsbanken Fonder
JANX icon

Handelsbanken Fonder’s Janux Therapeutics JANX Stock Holding History

Handelsbanken Fonder’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,800
Closed -$247K – 1522
2026
Q1 		$247K Hold
17,800
– – ﹤0.01% 1440
2025
Q4 		$246K Buy
17,800
+3,800
+27% +$89.4K ﹤0.01% 1465
2025
Q3 		$342K Hold
14,000
– – ﹤0.01% 1396
2025
Q2 		$323K Buy
14,000
+2,000
+17% +$52.7K ﹤0.01% 1403
2025
Q1 		$324K Hold
12,000
– – ﹤0.01% 1381
2024
Q4 		$642K Buy
+12,000
New +$635K ﹤0.01% 1188

Other funds holding JANX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder's JANX Position: Q2 2026 in Review

Handelsbanken Fonder sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 17,800 shares — an estimated $247K sold.

Handelsbanken Fonder first reported a position in JANX in Q4 2024 and held it in 6 quarters. The position peaked at $642K in Q4 2024. 61 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Handelsbanken Fonder reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Handelsbanken Fonder sold 17,800 Janux Therapeutics shares in Q2 2026, an estimated $247K.
  • Handelsbanken Fonder first reported a position in Janux Therapeutics in Q4 2024 and held it in 6 quarters.
  • Handelsbanken Fonder's Janux Therapeutics position peaked at $642K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.